Inhaled IPF Therapy LTI-03 Well-Tolerated in Healthy Volunteers
Lung Therapeutics’ LTI-03, an investigational inhaled therapy for idiopathic pulmonary fibrosis (IPF), was safe and well-tolerated in healthy volunteers, with no reports of serious adverse events (side effects) or discontinuations, according to a Phase 1a trial. “We are pleased that LTI-03 has passed this important safety milestone as…